Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.
AUTOR(ES)
Knapp, C C
RESUMO
The inhibitory and bactericidal activities of a novel cyclic peptide antibiotic, LY146032, and vancomycin against oxacillin-susceptible and oxacillin-resistant staphylococci were compared. The MICs for 90% of strains were two- to fourfold higher for vancomycin than for LY146032. MBC/MIC ratios for all strains were less than or equal to 2. In killing rate studies with four strains of staphylococci, there was no detectable growth in the presence of 4X the MIC of either LY146032 or vancomycin after 24 h of incubation.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=180623Documentos Relacionados
- In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.
- In vitro selection of bacteria resistant to LY146032, a new cyclic lipopeptide.
- Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.
- In vitro activity of LY146032, a new lipopeptide antibiotic, against gram-positive cocci.
- In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.
